Recombinant Tissue-Type Plasminogen Activator Plus Eptifibatide Versus Recombinant Tissue-Type Plasminogen Activator Alone in Acute Ischemic Stroke: Propensity Score-Matched Post Hoc Analysis [Clinical Sciences]

Conclusion— r-tPA plus eptifibatide showed a favorable direction of effect that was consistent across multiple approaches for AIS outcome evaluation. A phase III trial to establish the efficacy of r-tPA plus eptifibatide for improving AIS outcomes is warranted.

http://stroke.ahajournals.org/cgi/content/short/46/2/461?rss=1

Source: Stroke - January 26, 2015 Category: Neurology Authors: Adeoye, O., Sucharew, H., Khoury, J., Tomsick, T., Khatri, P., Palesch, Y., Schmit, P. A., Pancioli, A. M., Broderick, J. P., for The CLEAR-ER, IMS III, and ALIAS Part 2 Investigators Tags: Acute Cerebral Infarction, Emergency treatment of Stroke, Thrombolysis Clinical Sciences Source Type: research